| 4.065 0.005 (0.12%) | 02-13 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.8 | 1-year : | 5.6 |
| Resists | First : | 4.11 | Second : | 4.8 |
| Pivot price | 4.06 |
|||
| Supports | First : | 4.02 | Second : | 3.98 |
| MAs | MA(5) : | 4.05 | MA(20) : | 4.05  |
| MA(100) : | 3.41 |
MA(250) : | 5.61 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 16.6 | D(3) : | 21.2 |
| RSI | RSI(14): 59.4 | |||
| 52-week | High : | 12.36 | Low : | 2.04 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ THRX ] has closed above bottom band by 34.6%. Bollinger Bands are 95.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.07 - 4.09 | 4.09 - 4.11 |
| Low: | 4 - 4.03 | 4.03 - 4.05 |
| Close: | 4.02 - 4.06 | 4.06 - 4.1 |
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Wed, 14 Feb 2024
Theseus Pharmaceuticals' Strategic Merger and Corporate Restructuring - TipRanks.com - TipRanks
Thu, 01 Feb 2024
Theseus: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR - Seeking Alpha
Fri, 22 Dec 2023
THRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to ... - Business Wire
Mon, 27 Nov 2023
Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan - Yahoo Finance
Mon, 13 Nov 2023
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives - PR Newswire
Fri, 14 Jul 2023
THRX Tanks after Pausing Trial of Lead Cancer Candidate - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 84 (%) |
| Shares Short | 402 (K) |
| Shares Short P.Month | 585 (K) |
| EPS | -1.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.9 % |
| Return on Equity (ttm) | -25.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -3.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|